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Background: The clinical presentation of Bordetella pertussis can overlap with that of respiratory 
syncytial virus (RSV); however, management differs.
Hypothesis: First, the prevalence of B. pertussis is less than 2% among patients screened for RSV, 
and second the prevalence of B. parapertussis is also less than 2% among these patients. 
Methods: Nasal washings submitted to a clinical laboratory for RSV screening were tested for B. 
pertussis and B. parapertussis, using species-specific real-time polymerase chain reaction (PCR) 
assays. These were optimized to target conserved regions within a complement gene and the CarB 
gene, respectively. A Bordetella spp. genus-specific real-time PCR assay was designed to detect 
the Bhur gene of B. pertussis, B. parapertussis, and B. bronchiseptica. RSV A and B subtypes were 
tested by reverse transcription-PCR.
Results: Four hundred and eighty-nine clinical samples were tested. There was insufficient material 
to complete testing for one B. pertussis, 10 RSV subtype A, and four RSV subtype B assays. 
Bordetella pertussis was detected in 3/488 (0.6%) (95% CI 0.1% to 1.8%), while B. parapertussis was 
detected in 5/489 (1.0%) (95% CI 0.3% to 2.4%). Dual infection of B. pertussis with RSV and of B. 
parapertussis with RSV occurred in two and in three cases respectively. RSV was detected by PCR in 
127 (26.5%).
Conclusion: The prevalence of B. pertussis in nasal washings submitted for RSV screening was less 
than 2%. The prevalence of parapertussis may be higher than 2%.  RSV with B. pertussis and RSV 
with B. parapertussis coinfection do occur.
[WestJEM. 2008;9:135-140.]
INTRODUCTION
The clinical presentation of Bordetella pertussis can 
overlap with and be clinically indistinguishable from that 
of respiratory syncytial virus (RSV).1,2 The potential for Western Journal of Emergency Medicine                              136                                      Volume IX, n o . 3  :  August 2008 
Prevalence of B. pertussis in RSV samples   Walsh et al
morbidity and mortality is higher with B. pertussis.2,3 Apnea 
occurs in 15.9% of previously healthy infants less than six 
months of age who contract pertussis.4 Apnea rates for RSV 
are lower, even in hospitalized infants.5 This risk is largely 
confined to infants less than two months of age and to 
those with co-morbidities.6-9 Admission criteria reflect these 
differences with mandatory admission recommended for those 
with pertussis up to six months of age.10 Mandatory admission 
for infants with RSV is controversial, with conflicting 
published evidence and opinions, but many opt to admit all 
less than two months of age.11,12,13
RSV epidemiological trends have remained steady14 
whereas pertussis infections have climbed both locally (Kern 
County Department of Public Health data) and nationally15 
with genomic subtypes not contained in vaccinations being 
increasingly represented.16 Previous work among children 
admitted to intensive care for bronchiolitis in the UK, and 
among infants less than six months of age hospitalized with 
bronchiolitis in Finland, suggests that despite the apparently 
viral nature of their illness (typically RSV), pertussis is under 
diagnosed.1,17 However this experience is not universal with 
some reporting the opposite.18 These studies raise the question 
whether infants and toddlers screened for RSV should also be 
screened for B. pertussis.  
While baseline population prevalence data can help 
inform such a decision, these estimates from public health 
departments are of limited value. They reflect cases with more 
typical presentations in which the diagnosis was clinically 
suspected; even then they are prone to under reporting.19,20  
Determining the overall baseline-expected prevalence of 
B. pertussis in patients with presentations more typically 
associated with RSV requires large numbers. It also requires a 
sample representative of the full spectrum of RSV disease that 
presents for treatment (primarily bronchiolitis). We tested de-
identified specimens previously submitted for RSV screening 
to determine the prevalence of B. pertussis in this population. 
We considered that a prevalence of less than 2% would 
represent an acceptable miss rate for most emergency 
physicians (EPs) for pertussis and tested the hypothesis 
that the prevalence of B. pertussis is less than 2% in nasal 
washings screened for RSV. Our secondary hypothesis was 
that the prevalence of B. parapertussis is less than 2% in nasal 
washings screened for RSV.
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Figure 1. Specimen flow through the study.
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METHODS 
Our institutional review board exempted the study from 
review.
Setting: A single clinical laboratory serving an emergency 
department (ED), pediatric clinic, family practice clinic and a 
county hospital and a diagnostic testing laboratory specializing 
in the use of molecular amplification assays for the detection 
of viruses, bacteria, and fungi in biological specimens.
Nasal washings samples collected between October 2005 
and May 2006 were first tested for the RSV antigen by the 
clinical laboratory. They were collected in test tubes without 
additives using normal saline. The remaining part of each 
sample was refrigerated to 4ºC prior to being divided into 325 
μl aliquots into DNA- ase-free transport containers and frozen 
to -70°C. The flow of specimens is shown in Figure 1.
Upon receipt at the diagnostic testing laboratory the 
specimens were thawed, and DNA was extracted using 
an automated Corbett Robotics X-tractor Gene system. 
Extracted DNA from these specimens were subsequently 
tested by Bordetella pertussis and Bordetella parapertussis 
species-specific real-time polymerase chain reaction (PCR) 
assays designed and optimized to target conserved regions 
within a complement gene and the CarB gene, respectively. 
A Bordetella spp. genus-specific real-time PCR assay was 
also designed to detect the Bhur gene of B. pertussis, B. 
parapertussis, and B. bronchiseptica. The characteristics 
and detection limits of this PCR assay (detection limit for 
B. pertussis 100 copies per reaction, detection limits for B. 
parapertussis 10 copies per reaction) are shown in Figures 2 
and 3. Specificity was assessed by testing the assay against 
known samples of the viral, bacterial, and fungal pathogens 
listed in Table 1. No amplification for any of these agents was 
detectable for the B. pertussis, B. parapertussis or Bordetella 
ssp. assays. These assays are available for clinical use from a 
commercial CLIA approved laboratory.
For the RSV assays, RNA was extracted from the 
washings using either a modified protocol with the Corbett 
Robotics X-tractor Gene System or with the QIAamp Viral 
RNA purification kit (Qiagen, Valencia, CA). Extracted RNA 
was subsequently tested for RSV-A and RSV-B using two 
separate one-step reverse transcription PCR assays targeting 
Figure 3. B. parapertussis range of detection and standard curve ranging from 1 x 1010 copies to 1 x 102 copies. 
Table 1. Pathogens for which the real time probe and primer 
specificity was assessed.
Gardnerella vaginalis Candida parapiosis Bartonella bacilliformis
Neisseria gonorrhoea Candida tropicalis Bartonella quintana
Neisseria meningitidis Candida lustaniae Human rhinovirus 6
Trichomonas vaginalis Candida albicans Human rhinovirus 11
Chlamydia trachomatis Candida dublinesis Adenovirus type 10
Chlamydia pneumoniae Candida utilis Adenovirus
Ureaplasma urealyticum Candida krusei Coxsackie virus
Herpes simplex virus I Influenza A Cryptococcus neoformans
Herpes simplex virus II Influenza B Babesia microti
Human papilloma virus Aspergillus fumigans Bacteroides fragilis
Epstein Barr virus Human herpes virus 8 Mobiluncus curtsii
Cytomegalovirus Human herpes virus 6 Mobiluncus mulieris
Mycoplasma fermentens Canine herpes virus  Legionella pneumophilia
Mycoplasma pneumoniae HTLV 1 Brucellosis ovis
Mycoplasma genetalium Parainfluenza 2 Borrelia burgdorferi
Mycoplasma hominis Parainfluenza 3 Streptococcus pneumoniae
Moraxella catarrhalis
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genes, which encodes a phosphoprotein for each strain. The 
detection threshold for RSV-A and RSV-B was 100 copies per 
reaction. 
Because we were not allowed to use patient identifiers, 
we used total population characteristics for all RSV samples 
submitted to the clinical laboratory during the study period to 
estimate population characteristics. 
Statistical Analysis: Prevalence and exact confidence 
intervals were calculated for B. pertussis, B. parapertussis 
and RSV and co-infection. We tested the hypotheses that the 
proportion of cases screening positive for B. pertussis and B. 
parapertussis would exceed 2% with exact methods using 
STATA 9.2 (Stata Corp LP, College Station, TX).
RESULTS
The median age of the population sampled was 4.8 
months (IQR 8.2); 356/648 (54.9%) were male. Six hundred 
and forty-eight specimens were received at the clinical lab. 
Most of these, 571 (88.4%) came from the ED, 49 (7.6%) 
from the pediatric and family practice clinics, and 26 (4.0%) 
from inpatients. Four hundred and eighty-nine (75.5%) of 
these submitted clinical samples were captured for additional 
testing. There was insufficient material to complete testing 
for one B. pertussis, 10 RSV subtype A, and three RSV 
subtype B assays. Bordetella pertussis was detected in 3/488 
(0.61%) (95% CI 0.13% to 1.79%) while B. parapertussis was 
detected in 5/489 (1.02%) (95% CI 0.33% to 2.37%). Dual 
infection with B. pertussis and RSV was found in two cases. 
Dual infection with B. parapertussis and RSV occurred in 
three cases. The results are detailed in Table 2. One case of B. 
bronchiseptica (‘kennel cough’) was also found. RSV A was 
found in 75/479 (16%) samples and RSV B in 52/486 (11%). 
Local prevalence trends for the preceding 10 years are shown 
in Figure 4 to place the results in context. 
DISCUSSION
Despite the rising local and national trend of reported 
cases of B. pertussis at the time of the study, we found very 
low rates of co-infection of B. pertussis and RSV. Our study 
does provide some evidence for clinicians who discount 
concerns about missing pertussis during RSV season, even 
during the current apparent resurgence of pertussis. 
Our results are consistent with that of a retrospective 
study of 166 children less than six-years-old hospitalized with 
lower respiratory tract symptoms in which a 0.6% (95% CI: 
0.0% to 3.3%) prevalence was noted.1 However, Siberry et 
al.18 was performed at a low point in local disease prevalence 
(five cases in all age groups in Baltimore) and drawn from 
an older population than ours; the studies are therefore not 
directly comparable. Our results contrast with those of Korppi 
and Hiltunin,17 which found an 8% prevalence in infants 
hospitalized with bronchiolitis who were less than six months 
old. 
Our methodology allowed us to obtain large numbers 
of clinical specimens but not to obtain individual level 
clinical information on the patients from whom they were 
obtained, much less the clinicians’ reasons for ordering the 
test. This is a feature of studies using so called “discarded 
clinical specimens.” Such studies’ results are most useful 
inferentially when they find a high or a low prevalence of 
an infectious agent. They are useful in triangulation, i.e. 
supporting a particular hypothesis by three different research 
methodologies. Triangulation is warranted when investigating 
conditions with high morbidity (such as causes of apnea) or 
when existing research provides conflicting answers.
This study suggests that when the community prevalence 
of pertussis is low, (our reported prevalence was 7.9/100,000 
during the study period), and a 2% miss rate is acceptable 
to clinicians, routine screening for pertussis in patients 
suspected of having RSV is unwarranted. This is in contrast 
to studies that have looked at selected subgroups and found B. 
pertussis to be common. The definitiveness of this statement 
will depend on the results being replicated over a number of 
seasons.
 LIMITATIONS
Local test-ordering patterns may help explain our low 
RSV rate. The sampling would have included patients 
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Figure 4. The context in which our sampling was performed.  The 
box represents the sampling period.
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Table 2. Results by subtype
RSV B. pertussis + B. parapertussis +
RSV A +  75     (16%) 1     (0.2%) 2     (0.4%)
RSV B +  52     (11%) 1     (0.2%) 1     (0.2%)
RSV A - 404     (84%)
1     (0.2%) 2     (0.4%)
RSV B - 434     (89%)
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screened for RSV early and late in the bronchiolitis season 
when other viruses are generally responsible. In-patient 
screening samples required for cohorting would also have 
been included in this analysis. RSV testing may have been 
obtained in cases of fever without source, or as part of 
apparent-life threatening event (ALTE) evaluations. False-
negative PCR results for RSV are also a likely potential 
reason. This may in part be due to dilution of virus inherent 
in the collection of nasal aspirates. Initial specimen collection 
used unpreserved saline in clinical test tubes. RNA is less 
stable than DNA. During the uncontrolled phase (specimen 
going from patient to clinical laboratory) and despite 
refrigeration prior to aliquoting into DNA-ase-free containers, 
some RNA degradation could have occurred. Nasal aspirates 
have been shown to be markedly inferior to universal transport 
medium for room temperature (UTM-RT) based collection 
methods for PCR-based testing for respiratory viruses in 
general and RSV in particular.21,22 While this may artificially 
lower our detection of RSV it is less likely to have such an 
effect on Bordetella spp. Detection of bacterial DNA is much 
less susceptible to the collection method used (unpublished 
data). All of these factors may account for the difference 
between RSV detection in this and another contemporaneous 
study in our institution where a clinical diagnosis of 
bronchiolitis was the entry criterion and in which RSV 
prevalence was 55%.23
The use of nasal washings rather than nasopharyngeal 
swabs (NPS) could potentially have decreased the yield of 
pertussis. While only NPS are considered acceptable for 
culture, the sensitivity of PCR mitigates against the potential 
loss of sensitivity by our methods.
Mistaken attribution of respiratory illness to B. pertussis 
has been described due to poor PCR assay specificity but high 
sensitivity.24 We feel this is unlikely to be the case in our study 
based on the specificity testing results for our assay and the 
actual study results obtained.
We have not addressed here the broader epidemiology of 
those clinical presentations that typically prompt RSV testing. 
The clinical role for testing for these other agents is currently 
evolving. We could not control the age of patients whose 
samples were included; however, based on the age profile of 
the patients whose samples were submitted, our results should 
be considered applicable only to infants and toddlers. 
We included only samples from a single clinical 
laboratory serving a single county system of clinics and 
hospital sites. Although this system serves a mixed urban, 
suburban and rural population, our patients tend to be drawn 
from lower socio-economic groups. This would tend to 
increase the prevalence of infectious diseases in general and 
may overestimate the prevalence that would be found in a 
more affluent setting. On the other hand vaccine refusal, 
which increases vulnerability to pertussis, tends to occur in 
higher socio-economic groups. Local DPT vaccination and 
pertussis patterns mirror those of the rest of the state and 
country as a whole.
Our results must be viewed in the context of the overall 
prevalence of pertussis within the community. A higher 
prevalence could have changed our results, although the 
degree of change necessary to change the outcome is 
speculative. Nonetheless, although low by historical standards, 
prevalence was at a 10-year high during our study period. 
This is based on Department of Public Health reported case, 
data that inevitably carry their own limitations. Although the 
number of cases reported is low, it is likely an underestimate. 
It is estimated that between one-third and one in 20 of actual 
pertussis cases are reported.19,20 Nonetheless, the increasing 
trend of reported cases matches that for state and national 
reporting.
Our geographic locale is large. It is also a relatively 
sparsely populated, poor, and a medically underserved 
county with very low per person medical care expenditure,25 
again suggesting that the actual number of pertussis cases is 
probably higher than that reported. 
Future reports will address these limitations by enrolling 
only ED patients and addressing clinical variables and 
outcomes over a number of seasons.
CONCLUSION
In a combined outpatient clinic, ED, and inpatient 
population, the prevalence of B. pertussis in nasal washings 
submitted for RSV antigen screening was less than 2%. 
The prevalence of parapertussis may have been higher than 
2%. RSV with B. pertussis and RSV with B. parapertussis 
coinfection did occur.
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